CA2461290C - Modulation de cellules souches au moyen de proteines a doigts de zinc (zfp) - Google Patents

Modulation de cellules souches au moyen de proteines a doigts de zinc (zfp) Download PDF

Info

Publication number
CA2461290C
CA2461290C CA2461290A CA2461290A CA2461290C CA 2461290 C CA2461290 C CA 2461290C CA 2461290 A CA2461290 A CA 2461290A CA 2461290 A CA2461290 A CA 2461290A CA 2461290 C CA2461290 C CA 2461290C
Authority
CA
Canada
Prior art keywords
cell
cells
gene
zfp
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2461290A
Other languages
English (en)
Other versions
CA2461290A1 (fr
Inventor
Michael Moore
Timothy Farries
Trevor Collingwood
Fyodor Urnov
Alan P. Wolffe (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangamo Therapeutics Inc
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Publication of CA2461290A1 publication Critical patent/CA2461290A1/fr
Application granted granted Critical
Publication of CA2461290C publication Critical patent/CA2461290C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)

Abstract

L'invention concerne des procédés et des compositions permettant de modifier des cellules souches au moyen d'une ou de plusieurs ZFP. De tels procédés et compositions sont utiles pour faciliter des procédés tels que, par exemple, la dédifférenciation cellulaire, la différentiation de cellules souches dans le phénotype souhaité, la propagation de cellules souches et/ou pour faciliter le clonage.
CA2461290A 2001-09-24 2002-09-24 Modulation de cellules souches au moyen de proteines a doigts de zinc (zfp) Expired - Lifetime CA2461290C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32461901P 2001-09-24 2001-09-24
US60/324,619(CIP) 2001-09-24
US36725202P 2002-03-21 2002-03-21
US60/367,252(CIP) 2002-03-21
US37417602P 2002-04-17 2002-04-17
US60/374,176(CIP) 2002-04-17
PCT/US2002/030413 WO2003027247A2 (fr) 2001-09-24 2002-09-24 Modulation de cellules souches au moyen de proteines a doigts de zinc (zfp)

Publications (2)

Publication Number Publication Date
CA2461290A1 CA2461290A1 (fr) 2003-04-03
CA2461290C true CA2461290C (fr) 2014-11-25

Family

ID=27406339

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2461290A Expired - Lifetime CA2461290C (fr) 2001-09-24 2002-09-24 Modulation de cellules souches au moyen de proteines a doigts de zinc (zfp)

Country Status (4)

Country Link
US (3) US8735153B2 (fr)
EP (2) EP1435779A4 (fr)
CA (1) CA2461290C (fr)
WO (1) WO2003027247A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7734423B2 (en) * 2005-09-23 2010-06-08 Crowley Davis Research, Inc. Method, system, and apparatus for virtual modeling of biological tissue with adaptive emergent functionality
WO2008118957A2 (fr) 2007-03-26 2008-10-02 The Government Of U.S.A As Represented By The Secretary Of The Department Of Health & Human Services Procédés de modulation de la différentiation des cellules souches embryonnaires
US20090070087A1 (en) * 2007-09-07 2009-03-12 Newman Richard D Virtual tissue with emergent behavior and modeling method for producing the tissue
US20100304480A1 (en) * 2007-10-19 2010-12-02 Goodell Margaret A Hematopoietic Fingerprints: Methods of Use
EP2227540A4 (fr) * 2007-11-29 2011-11-02 Children S Hospital Of Orange County Dédifférenciation de cellules humaines
WO2010005527A1 (fr) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Traitement de maladies oculaires et d’une néovascularisation excessive utilisant un traitement combiné
WO2010056808A2 (fr) * 2008-11-12 2010-05-20 The Regents Of The University Of California Compositions et procédés pour reprogrammer et redifférencier des cellules
CA2772619C (fr) 2009-09-04 2019-07-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procede d'amelioration de la stabilite du genome et de l'elongation du telomere dans des cellules souches embryonnaires
EP2550356A4 (fr) * 2010-03-25 2013-09-25 Int Stem Cell Corp Méthode permettant de modifier le stade de différenciation d'une cellule et compositions afférentes
WO2012054896A1 (fr) * 2010-10-22 2012-04-26 Biotime Inc. Méthodes de modification des réseaux de régulation transcriptionnelle dans des cellules souches
JP6294079B2 (ja) 2011-01-25 2018-03-14 ミノル シル ホン コー 膵臓幹細胞及び前駆細胞のためのマーカーとしてのｚｓｃａｎ４及びその使用
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
CN105658792B (zh) * 2012-02-28 2020-11-10 西格马-奥尔德里奇有限责任公司 靶向组蛋白乙酰化
US9512406B2 (en) 2013-12-20 2016-12-06 The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone Generating hepatocytes
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
WO2015163823A1 (fr) * 2014-04-23 2015-10-29 Agency For Science, Technology And Research Procédés de reprogrammation cellulaire
EP2949342A1 (fr) * 2014-05-28 2015-12-02 Geneuro SA Médicaments antirétroviraux ciblant un rétrovirus endogène humain
WO2016014794A1 (fr) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Procédés et compositions pour moduler l'ingénierie génomique médiée par les nucléases dans des cellules souches hématopoïétiques
CN113699113A (zh) 2014-09-16 2021-11-26 桑格摩治疗股份有限公司 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
WO2016049230A1 (fr) 2014-09-24 2016-03-31 City Of Hope Variants de vecteur de virus adénoassocié pour une édition de haute efficacité du génome et procédés correspondants
EP3288570A4 (fr) * 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Cellules souches modifiées et leurs utilisations
CN105693842B (zh) * 2016-01-29 2019-09-24 中国科学院广州生物医药与健康研究院 NCoR/SMRT蛋白复合体在调节细胞命运转变中的应用
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
JP7584299B2 (ja) 2018-05-23 2024-11-15 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現
JP2022533713A (ja) 2019-05-21 2022-07-25 サンガモ セラピューティクス， インコーポレイテッド 調節性ｔ細胞における制御された導入遺伝子発現
WO2021028359A1 (fr) 2019-08-09 2021-02-18 Sangamo Therapeutics France Expression régulée de récepteurs d'antigènes chimériques dans des lymphocytes t
WO2022133062A1 (fr) * 2020-12-16 2022-06-23 Epicrispr Biotechnologies, Inc. Systèmes et procédés pour modifier les caractéristiques d'une cellule
IL311610A (en) 2021-09-21 2024-05-01 Scribe Therapeutics Inc Engineered CASX suppressor systems
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
WO2023141602A2 (fr) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Rétrons modifiés et méthodes d'utilisation
WO2024036148A1 (fr) * 2022-08-08 2024-02-15 A2 Biotherapeutics, Inc. Compositions et méthodes pour traitement de cancers du sang
AU2023329392A1 (en) 2022-08-25 2025-02-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
EP4771154A2 (fr) 2023-09-01 2026-07-08 Renagade Therapeutics Management Inc. Systèmes et compositions d'édition génique, et méthodes de traitement du syndrome vexas
WO2025174765A1 (fr) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition génique et comme vaccins et agents thérapeutiques

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US143568A (en) 1873-10-14 Improvement in stays for ships sails
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
PT87133B (pt) 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US6258354B1 (en) 1989-09-29 2001-07-10 Joel S. Greenberger Method for homing hematopoietic stem cells to bone marrow stromal cells
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1994016718A1 (fr) 1991-07-08 1994-08-04 Neurospheres Ltd. Modification genetique de cellules souches nerveuses
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5980885A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
FI935929L (fi) 1991-07-08 1994-02-02 Neurospheres Ltd Ny vaext regulerande faktor i stamcellen som foermaor foeroeka in vitro
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
ATE221117T1 (de) 1992-10-16 2002-08-15 Neurospheres Holdings Ltd Remyelination unter verwendung von neuronalen stammzellen
ATE483795T1 (de) 1992-10-28 2010-10-15 Neurospheres Holdings Ltd Biologische faktoren und neuronale stammzellen
US5766948A (en) 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
US5503022A (en) 1993-01-25 1996-04-02 Barone; Larry A. Marine impeller tester
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
WO1995005843A1 (fr) 1993-08-25 1995-03-02 Systemix, Inc. Procede de production d'une population de cellules souches hematopoietiques fortement enrichie
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
JP4012243B2 (ja) 1994-01-18 2007-11-21 ザ スクリップス リサーチ インスティチュート 亜鉛フィンガータンパク質誘導体およびそのための方法
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
CA2196419C (fr) 1994-08-20 2007-08-21 Yen Choo Ameliorations concernant des proteines de liaison permettant de reconnaitre l'adn
FI971168L (fi) * 1994-09-23 1997-03-20 Neurospheres Holdings Ltd Keskushermoston toiminnan ja häiriön in vitro -mallit
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5935811A (en) 1995-03-03 1999-08-10 California Institute Of Technology Neuron-restrictive silencer factor nucleic acids
US5668810A (en) * 1995-04-26 1997-09-16 Scientific-Atlanta, Inc. Data transmission protocol method and apparatus
WO1998032840A1 (fr) 1997-01-24 1998-07-30 Asahi Medical Co., Ltd. Procede de separation des cellules
US6011197A (en) 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
IL134643A0 (en) 1997-08-27 2001-04-30 Ariad Gene Therapeutics Inc Chimeric transcriptional activators and compositions and uses related thereto
GB9724829D0 (en) 1997-11-21 1998-01-21 Muller Rolf Transcription factor
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2001004296A1 (fr) 1999-07-12 2001-01-18 Mcgill University Polypeptides rbp1 et leurs utilisations
EP1276859B1 (fr) 2000-04-28 2007-02-07 Sangamo Biosciences Inc. Modification ciblee de la structure de chromatine
US6954891B1 (en) * 2001-10-29 2005-10-11 Cypress Semiconductor Corp. Technique for payload-independent frame delineation engine for optical data transport
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
US9401201B1 (en) 2015-05-22 2016-07-26 Qualcomm Incorporated Write driver for memory

Also Published As

Publication number Publication date
US8735153B2 (en) 2014-05-27
US20170224741A1 (en) 2017-08-10
WO2003027247A2 (fr) 2003-04-03
WO2003027247A3 (fr) 2003-05-22
US9624509B2 (en) 2017-04-18
EP2266396A2 (fr) 2010-12-29
EP1435779A2 (fr) 2004-07-14
CA2461290A1 (fr) 2003-04-03
US10888589B2 (en) 2021-01-12
EP2266396A3 (fr) 2011-06-15
US20060251642A1 (en) 2006-11-09
US20140234970A1 (en) 2014-08-21
EP1435779A4 (fr) 2005-06-01

Similar Documents

Publication Publication Date Title
US10888589B2 (en) Modulation of stem cells using zinc finger proteins
Javed et al. Pou2f1 and Pou2f2 cooperate to control the timing of cone photoreceptor production in the developing mouse retina
Baba et al. Constitutively active β-catenin confers multilineage differentiation potential on lymphoid and myeloid progenitors
AU2016342179B2 (en) Multi-lineage hematopoietic precursor cell production by genetic programming
EP2673358B1 (fr) Production de précurseurs hématopoïétiques obtenus par programmation
US20060014286A1 (en) Ligand-controlled regulation of endogenous gene expression
US6933113B2 (en) Modulation of endogenous gene expression in cells
US6919204B2 (en) Modulation of gene expression using localization domains
AU2004274957B2 (en) Engineered zinc finger proteins for regulation of gene expression
KR20070060115A (ko) 단백질 생산을 위한 조성물 및 방법
CN110050061A (zh) 从具有MeCP2破坏的诱导多能干细胞生成成熟谱系
Li et al. Targeted disruption of TCF12 reveals HEB as essential in human mesodermal specification and hematopoiesis
US20020164575A1 (en) Gene identification
Navarro et al. Generation of iPSCs from genetically corrected Brca2 hypomorphic cells: implications in cell reprogramming and stem cell therapy
US6780590B2 (en) Gene identification
US20210355441A1 (en) Generation of hoxa-expressing hemogenic endothelium with enhanced t cell potential from hpscs
AU2002330097B2 (en) Modulation of stem cells using zinc finger proteins
WO2002026960A2 (fr) Modulation de l'expression genique au moyen de domaines de localisation
Javed et al. Ikaros family proteins regulate developmental windows in the mouse retina through convergent and divergent transcriptional programs
AU2002330097A1 (en) Modulation of stem cells using zinc finger proteins
Mayers et al. Establishment of an erythroid progenitor cell line capable of enucleation achieved with an inducible c-Myc vector
HK40124208A (en) Methods and compositions for stem cell differentiation
Wang Regulation of B cell development by posttranslational modification of Ebf1
Pflumio et al. HOXC4 homeoprotein efficiently expands human hematopoietic stem cells and triggers similar molecular alterations as...
WO2000034329A2 (fr) Signal de differentiation

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220926